This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Dana-Farber-Cancer Institute Inc.. Active years: 1992-2007.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1992-2007
Title: Linda K Clayton: Innovator in Cancer Research
Introduction
Linda K Clayton is a prominent inventor based in Jamaica Plain, MA (US). She has made significant contributions to the field of cancer research, particularly in the area of apoptosis and HIV research. With a total of 2 patents, her work has the potential to impact therapeutic strategies in oncology.
Latest Patents
One of her latest patents is focused on methods of identifying agents that enhance caspase activity. This invention describes techniques for enhancing caspase activity and promoting apoptosis in lymphocytes. Another notable patent involves the alteration of the ability of soluble CD4 fragments to bind HIV. This patent details DNA encoding modified soluble human CD4 fragments, which have a different binding ability to the HIV gp120 envelope protein compared to standard soluble human CD4 fragments.
Career Highlights
Linda K Clayton is affiliated with the Dana-Farber Cancer Institute Inc., where she conducts her research. Her work is crucial in understanding the mechanisms of cancer cell death and the interactions between HIV and immune cells.
Collaborations
Throughout her career, Linda has collaborated with esteemed colleagues such as Ellis L Reinherz and Timothy D Ocain. These collaborations have further enriched her research and contributed to advancements in the field.
Conclusion
Linda K Clayton is a dedicated inventor whose work in cancer research and HIV has led to valuable patents. Her contributions continue to pave the way for innovative therapeutic approaches.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile